New stock news: Zhejiang Jingxin Pharmaceutical's (688266.SH) Hong Kong IPO prospectus fails.

According to the Securities Times app, the Hong Kong stock prospectus submitted by Suzhou Zejing Biopharmaceutical Co., Ltd. (referred to as Zejing Pharmaceuticals, 688266.SH) on December 19, 2025, expired on June 19, 2026, six months after submission. Zhong Jin Company was the exclusive sponsor when the prospectus was submitted.